Metabolic
Flexibility Genes
True health requires the ability to seamlessly switch between burning carbohydrates and burning fats. This panel measures the expression of glucose transporter and lipid oxidation genes.
Quantifying Substrate Transition
The capacity to switch between fat and glucose as fuel is one of the processes researchers track in metabolic health. Indirect calorimetry measures whole-body gas exchange. Transcriptomics measures gene expression in the cells of the sample provided — for a blood panel, circulating cells.
Tracking SLC2A4 and PPARG describes the transcription of two genes in the glucose-handling programme. Tracking the fatty-acid oxidation enzyme CPT1B alongside PDHA1 describes the transcription of two genes in the substrate-switching programme.
Key Pathway Targets
Glucose Transporter Type 4
Facilitates insulin-stimulated glucose uptake into muscle and adipose tissues.
Peroxisome Proliferator-Activated Receptor Gamma
Master transcriptional regulator of adipogenesis and lipid storage. Pharmacological PPARγ agonists improve insulin sensitivity; the transcript's abundance is not itself a measure of insulin sensitivity.
Carnitine Palmitoyltransferase 1B
Rate-limiting enzyme for mitochondrial fatty acid beta-oxidation (lipid burning).
Pyruvate Dehydrogenase E1 Subunit Alpha 1
Links glycolysis to the Krebs cycle, serving as a critical gatekeeper for glucose oxidation.
Why DNA Tells Only Half the Metabolic Flexibility Story
Your DNA carries common variants in genes such as PPARG and FTO. FTO variants associate with body mass and appetite regulation. None of this changes over your lifetime, and none of it says what those genes are doing right now.
Transcriptomics (RNA) measures gene expression as it is happening, in the cells the sample contains. It does not report muscle or adipose tissue directly.
Protein Panels vs. Transcriptomics
Traditional blood panels measure circulating metabolites and proteins. Transcriptomics measures the gene transcription upstream of them. The two describe different layers of the same biology.
| Protein Marker | What It Measures | RNA Target |
|---|---|---|
| Respiratory Exchange (RER) | Whole-body ratio of CO2 produced to O2 consumed, indicating which fuel is being oxidised. | SLC2A4 (GLUT4) |
| Fasting Glucose | Blood glucose after an overnight fast. | — |
| Serum Free Fatty Acids | Concentration of non-esterified fatty acids in circulation. | PPARA / PPARD |
WHAT A TRANSCRIPTIONAL PANEL DOES NOT TELL YOU
- × That you have, or do not have, any medical condition. This panel reports gene activity, not diagnoses.
- × Whether a therapy is working. Transcript levels move for many reasons — sleep, a recent infection, the time of day, how long since you last ate or trained — and a change in them is not evidence that any intervention succeeded or failed.
- × What your results will be next month. Every value describes the moment the sample was drawn. Single-timepoint transcript measurements carry substantial within-person variability.
- × What is happening in a tissue the sample did not come from. These panels run on a blood sample. A blood transcript level is not a muscle, liver, brain or adipose measurement.
The Substrate Switching Cascade
Metabolic flexibility is controlled by molecular gatekeepers that direct traffic between glucose and lipid oxidation pathways. Muscle cells must dynamically open or close these gates based on nutrient availability and hormone levels.
Insulin Binding
Dietary glucose intake triggers insulin release, activating membrane receptors.
Glucose Import
Insulin moves a pre-existing pool of GLUT4 vesicles to the cell membrane, where the transporter lets glucose diffuse in down its gradient. This step needs no new SLC2A4 transcription (PMID 31175156).
Glucose Oxidation
The pyruvate dehydrogenase complex is switched on by dephosphorylation — PDK4 inhibits it, PDP phosphatases release it — and converts pyruvate to acetyl-CoA for the TCA cycle (PMID 12676647).
Lipid Gatekeeper
Under fasting conditions, CPT1B converts long-chain acyl-CoA to acylcarnitine at the outer mitochondrial membrane, the committed step into beta-oxidation. Acute flux is gated by relief of malonyl-CoA inhibition rather than by transcript level.
Restoring Metabolic Adaptiveness
These interventions utilize nutrient deprivation and muscular contraction to force cells to switch substrates and rebuild flexible metabolic pathways.
Low-Carbohydrate & Ketogenic Nutrition
Deprives the body of dietary glucose, associated with higher transcription of the fatty-acid oxidation enzyme CPT1B and of ketone metabolic enzymes.
High-Intensity Interval Training (HIIT)
Rapidly depletes intramuscular glycogen stores, associated with higher SLC2A4 expression after exercise.
Green Tea Extract (EGCG)
Dietary supplementPolyphenol compounds that support insulin signaling pathways and lipid beta-oxidation enzyme transcription.
Intermittent Fasting
Creates regular periods of low insulin signaling, shifting cells toward lipid mobilisation. Glycolysis is downregulated, never switched off.
Therapies That Act on These Genes
These therapies act on genes this panel reports. Biomeme does not prescribe, supply, recommend or evaluate any of them, and listing one here is not a claim that it works. Several are available only by prescription; some are not approved for any use. Where the published evidence is thin or points the other way, the card says so.
MOTS-c
Not approved for any useStudied in preclinical models for effects on metabolic signaling. Not approved for any use, and there are no published human trials. Note that AMPK is regulated post-translationally, so "AMPK expression" is not the mechanism by which anything activates it (PMID 22436748).
Testosterone / TRT
Prescription only · Controlled substance (Schedule III)Prescription testosterone is a Schedule III controlled substance, approved for specific medical conditions. Biomeme makes no claim about its use for any other purpose.
HRT
Prescription onlyPrescription hormone therapy. On the inflammatory marker with the most pooled data, oral preparations raised CRP by 37.6% while transdermal had no effect (PMID 16918589).
GLP-1 receptor agonists
Prescription onlyIn a meta-analysis of 52 randomized trials in type 2 diabetes, GLP-1 receptor agonists lowered CRP (SMD -0.63, 95% CI -1.03 to -0.23); the IL-6 result is inconsistent across meta-analyses of the same trial base (PMID 40230207). These are circulating protein measurements, not transcriptional ones.
Scientific Citations (6)
- [1] Sugden MC, Holness MJ. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab. 2003;284(5):E855-862.
- [2] Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538-554.
- [3] Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.
- [4] Klip A, McGraw TE, James DE. Thirty sweet years of GLUT4. J Biol Chem. 2019;294(30):11369-11381.
- [5] Schlaepfer IR, Joshi M. CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential. Endocrinology. 2020;161(2):bqz046.
- [6] Ren Y, Chen Y, Zheng W, et al. The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2025;27(7):3607-3626.
The Biomeme Molecular Ecosystem
From deep whole-transcriptome sequencing in the laboratory to rapid point-of-care instrumentation in the field.
High-Depth RNA Sequencing
Processed at One Health Labs, Biomeme's CLIA-certified laboratory, using Illumina NovaSeq high-depth paired-end RNA sequencing. Samples are collected in venous PAXgene blood RNA tubes to stabilize cellular transcription at the moment of draw.
Biomeme/5 Handheld Platform
Beyond central-lab genomics, Biomeme engineers patented, battery-powered real-time PCR instruments. Our deployable hardware brings decentralized molecular detection directly to the field and clinical points of care.
Curious how we measure this?
Learn about the foundational science of Transcriptomics and how Biomeme brings molecular profiling to the point of need.
Ready to Learn More?
Explore how Biomeme's capabilities are being deployed across the Wellness landscape.
ABOUT THESE PANELS
Biomeme's wellness transcriptomic panels are general wellness products. They report gene activity to support a healthy lifestyle. They are not intended to diagnose, treat, cure, mitigate or prevent any disease or condition, and they are not a substitute for evaluation by a licensed healthcare professional. Results describe the state of the measured transcripts at the moment the sample was taken.